Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines

Radek Jorda; Nina Sacerdoti-Sierra; Jiří Voller; Libor Havlíček; Kateřina Kráčalíková; Matthew W. Nowicki; Abedelmajeed Nasereddin; Vladimír Kryštof; Miroslav Strnad; Malcolm D. Walkinshaw; Charles L. Jaffe

doi:10.1016/j.bmcl.2011.05.076

Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines

Radek Jorda, Nina Sacerdoti-Sierra, Jiří Voller, Libor Havlíček, Kateřina Kráčalíková, Matthew W. Nowicki, Abedelmajeed Nasereddin, Vladimír Kryštof, Miroslav Strnad, Malcolm D. Walkinshaw, Charles L. Jaffe

The Hebrew University of Jerusalem

Research output: Contribution to journal › Article › peer-review

Abstract

We report here results of screening directed to finding new anti-leishmanial drugs among 2,6-disubstituted purines and corresponding 3,7-disubstituted pyrazolo[4,3-d]pyrimidines. These compounds have previously been shown to moderately inhibit human cyclin-dependent kinases. Since some compounds reduced viability of axenic amastigotes of Leishmania donovani, we screened them for interaction with recombinant leishmanial cdc-2 related protein kinase (CRK3/CYC6), an important cell cycle regulator of the parasitic protozoan. Eighteen pairs of corresponding isomers were tested for viability of amastigotes and for inhibition of CRK3/CYC6 kinase activity. Some compounds (9A, 12A and 13A) show activity against amastigotes with EC₅₀ in a range 1.5-12.4 μM. Structure-activity relationships for the tested compounds are discussed and related to the lipophilicity of the compounds.

Original language	English
Pages (from-to)	4233-4237
Number of pages	5
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	21
Issue number	14
DOIs	https://doi.org/10.1016/j.bmcl.2011.05.076
State	Published - 15 Jul 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cyclin-dependent kinase
Inhibitor
Leishmania
Therapy

All Science Journal Classification (ASJC) codes

Biochemistry
Molecular Medicine
Molecular Biology
Pharmaceutical Science
Drug Discovery
Clinical Biochemistry
Organic Chemistry

Access to Document

10.1016/j.bmcl.2011.05.076

Cite this

Jorda, R., Sacerdoti-Sierra, N., Voller, J., Havlíček, L., Kráčalíková, K., Nowicki, M. W., Nasereddin, A., Kryštof, V., Strnad, M., Walkinshaw, M. D., & Jaffe, C. L. (2011). Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines. Bioorganic and Medicinal Chemistry Letters, 21(14), 4233-4237. https://doi.org/10.1016/j.bmcl.2011.05.076

@article{4d3c447be58e4795873e53eede346d71,

title = "Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines",

abstract = "We report here results of screening directed to finding new anti-leishmanial drugs among 2,6-disubstituted purines and corresponding 3,7-disubstituted pyrazolo[4,3-d]pyrimidines. These compounds have previously been shown to moderately inhibit human cyclin-dependent kinases. Since some compounds reduced viability of axenic amastigotes of Leishmania donovani, we screened them for interaction with recombinant leishmanial cdc-2 related protein kinase (CRK3/CYC6), an important cell cycle regulator of the parasitic protozoan. Eighteen pairs of corresponding isomers were tested for viability of amastigotes and for inhibition of CRK3/CYC6 kinase activity. Some compounds (9A, 12A and 13A) show activity against amastigotes with EC50 in a range 1.5-12.4 μM. Structure-activity relationships for the tested compounds are discussed and related to the lipophilicity of the compounds.",

keywords = "Cyclin-dependent kinase, Inhibitor, Leishmania, Therapy",

author = "Radek Jorda and Nina Sacerdoti-Sierra and Ji{\v r}{\'i} Voller and Libor Havl{\'i}{\v c}ek and Kate{\v r}ina Kr{\'a}{\v c}al{\'i}kov{\'a} and Nowicki, \{Matthew W.\} and Abedelmajeed Nasereddin and Vladim{\'i}r Kry{\v s}tof and Miroslav Strnad and Walkinshaw, \{Malcolm D.\} and Jaffe, \{Charles L.\}",

note = "Funding Information: The work was supported by grants from the Czech Science Foundation (204/08/0511; 301/08/1649), from the Ministry of Education, Youth and Sports of the Czech Republic (MSM 6198959216) and by a grant of the European Commission (Contract No. LSHB-CT-2004-503467; C.L.J.). The Center for Translational and Chemical Biology and Edinburgh Protein Production Facility (University of Edinburgh) were funded by the Wellcome Trust and the Biotechnology and Biological Sciences Research Council. C.L.J. holds the Michael and Penny Feiwel Chair in Dermatology. We are very grateful to Dr. Jeremy C. Mottram for contributing constructs of recombinant CRK3 and CYC6.",

year = "2011",

month = jul,

day = "15",

doi = "10.1016/j.bmcl.2011.05.076",

language = "الإنجليزيّة",

volume = "21",

pages = "4233--4237",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Ltd.",

number = "14",

}

Jorda, R, Sacerdoti-Sierra, N, Voller, J, Havlíček, L, Kráčalíková, K, Nowicki, MW, Nasereddin, A, Kryštof, V, Strnad, M, Walkinshaw, MD & Jaffe, CL 2011, 'Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines', Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 14, pp. 4233-4237. https://doi.org/10.1016/j.bmcl.2011.05.076

TY - JOUR

T1 - Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines

AU - Jorda, Radek

AU - Sacerdoti-Sierra, Nina

AU - Voller, Jiří

AU - Havlíček, Libor

AU - Kráčalíková, Kateřina

AU - Nowicki, Matthew W.

AU - Nasereddin, Abedelmajeed

AU - Kryštof, Vladimír

AU - Strnad, Miroslav

AU - Walkinshaw, Malcolm D.

AU - Jaffe, Charles L.

N1 - Funding Information: The work was supported by grants from the Czech Science Foundation (204/08/0511; 301/08/1649), from the Ministry of Education, Youth and Sports of the Czech Republic (MSM 6198959216) and by a grant of the European Commission (Contract No. LSHB-CT-2004-503467; C.L.J.). The Center for Translational and Chemical Biology and Edinburgh Protein Production Facility (University of Edinburgh) were funded by the Wellcome Trust and the Biotechnology and Biological Sciences Research Council. C.L.J. holds the Michael and Penny Feiwel Chair in Dermatology. We are very grateful to Dr. Jeremy C. Mottram for contributing constructs of recombinant CRK3 and CYC6.

PY - 2011/7/15

Y1 - 2011/7/15

N2 - We report here results of screening directed to finding new anti-leishmanial drugs among 2,6-disubstituted purines and corresponding 3,7-disubstituted pyrazolo[4,3-d]pyrimidines. These compounds have previously been shown to moderately inhibit human cyclin-dependent kinases. Since some compounds reduced viability of axenic amastigotes of Leishmania donovani, we screened them for interaction with recombinant leishmanial cdc-2 related protein kinase (CRK3/CYC6), an important cell cycle regulator of the parasitic protozoan. Eighteen pairs of corresponding isomers were tested for viability of amastigotes and for inhibition of CRK3/CYC6 kinase activity. Some compounds (9A, 12A and 13A) show activity against amastigotes with EC50 in a range 1.5-12.4 μM. Structure-activity relationships for the tested compounds are discussed and related to the lipophilicity of the compounds.

AB - We report here results of screening directed to finding new anti-leishmanial drugs among 2,6-disubstituted purines and corresponding 3,7-disubstituted pyrazolo[4,3-d]pyrimidines. These compounds have previously been shown to moderately inhibit human cyclin-dependent kinases. Since some compounds reduced viability of axenic amastigotes of Leishmania donovani, we screened them for interaction with recombinant leishmanial cdc-2 related protein kinase (CRK3/CYC6), an important cell cycle regulator of the parasitic protozoan. Eighteen pairs of corresponding isomers were tested for viability of amastigotes and for inhibition of CRK3/CYC6 kinase activity. Some compounds (9A, 12A and 13A) show activity against amastigotes with EC50 in a range 1.5-12.4 μM. Structure-activity relationships for the tested compounds are discussed and related to the lipophilicity of the compounds.

KW - Cyclin-dependent kinase

KW - Inhibitor

KW - Leishmania

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=79959911608&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2011.05.076

DO - 10.1016/j.bmcl.2011.05.076

M3 - مقالة

C2 - 21683592

SN - 0960-894X

VL - 21

SP - 4233

EP - 4237

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

IS - 14

ER -

Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines

Abstract

UN SDGs

Keywords

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this